ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others

Clinical Microbiology and Infection

Volumn 20, Issue S3, 2014, Pages 27-46

  Tortorano, A M ^a   Richardson, M ^b,c   Roilides, E ^d   van Diepeningen, A ^e   Caira, M ^f   Munoz, P ^g   Johnson, E ^h   Meletiadis, J ⁱ   Pana, Z D ^d   Lackner, M ^j   Verweij, P ^k,l   Freiberger, T ^m   Cornely, O A ⁿ   Arikan Akdagli, S ^o   Dannaoui, E ^p   Groll, A H ^q   Lagrou, K ^r   Chakrabarti, A ^s   Lanternier, F ^t,u   Pagano, L ^f   Skiada, A ^v   Akova, M ^o   Arendrup, M C ^w   Boekhout, T ^e,x,y   Chowdhary, A ^z   Cuenca Estrella, M ^aa   Guinea, J ^g   Guarro, J ^ab   de Hoog, S ^e   Hope, W ^ac   Kathuria, S ^z   Lortholary, O ^t,ad   Meis, J F ^k,ae   Ullmann, A J ^af   Petrikkos, G ^v   Lass Florl C ^j   more..

^a UNIVERSITY OF MILAN   (Italy)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^e CBS KNAW FUNGAL BIODIVERSITY CENTRE   (Netherlands)

^f CATHOLIC UNIVERSITY   (Italy)

^g HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^h NHS BLOOD AND TRANSPLANT   (United Kingdom)

ⁱ NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^j INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^k RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^l Nijmegen Institute for Infection   (Netherlands)

^m MASARYK UNIVERSITY   (Czech Republic)

ⁿ UNIVERSITY OF COLOGNE   (Germany)

^o HACETTEPE UNIVERSITY   (Turkey)

^p HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^q UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^r UNIVERSITY OF LEUVEN   (Belgium)

^s POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^t HÔPITAL NECKER ENFANTS MALADES   (France)

^u INSTITUT PASTEUR   (France)

^v UNIVERSITY OF ATHENS   (Greece)

^w STATENS SERUM INSTITUT   (Denmark)

^x UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^y SECOND MILITARY MEDICAL UNIVERSITY   (China)

^z UNIVERSITY OF DELHI   (India)

^aa INSTITUTO DE SALUD CARLOS III   (Spain)

^ab UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^ac UNIVERSITY OF LIVERPOOL   (United Kingdom)

^ad CNRS   (France)

^ae CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^af UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

more..

Author keywords

Acremonium; Fusarium; Hyalohyphomycosis; Paecilomyces; Scedosporium; Scopulariopsis

Indexed keywords

ANTIFUNGAL AGENT; POSACONAZOLE; VORICONAZOLE;

ACREMONIUM; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; FUNGAL VIRULENCE; FUSARIOSIS; FUSARIUM; FUSARIUM SOLANI; HOSPITAL INFECTION; HUMAN; HYALOHYPHOMYCOSIS; IMMUNOCOMPROMISED PATIENT; INFECTION SENSITIVITY; PAECILOMYCES; PAECILOMYCOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSEUDALLESCHERIASIS; PURPUREOCILLIUM; PURPUREOCILLIUM INFECTION; SCEDOSPORIUM; SCEDOSPORIUM APIOSPERMUM; SCOPULARIOPSIS;

ACREMONIUM; FUSARIUM; HYALOHYPHOMYCOSIS; PAECILOMYCES; SCEDOSPORIUM; SCOPULARIOPSIS;

ANTIFUNGAL AGENTS; FUSARIUM; HUMANS; HYALOHYPHOMYCOSIS; SCEDOSPORIUM;

EID: 84895796957     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12465     Document Type: Article

References (304)

1. Nucci M, Garnica M, Gloria AB et al. Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia in Brazil. Clin Microbiol Infect 2013; 19: 745-751.
2. Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev 2007; 20: 695-704.
3. Nucci M, Anaissie E. Emerging fungi. Infect Dis Clin North Am 2006; 20: 563-579.
4. Nucci M, Anaissie EJ, Queiroz-Telles F et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer 2003; 98: 315-319.
5. Nucci M. Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients. Curr Opin Infect Dis 2003; 16: 607-612.
6. Lamaris GA, Chamilos G, Lewis RE, Safdar A, Raad II, Kontoyiannis DP. Scedosporium infection in a tertiary care cancer center: a review of 25 cases from 1989-2006. Clin Infect Dis 2006; 43: 1580-1584.
7. Pastor FJ, Guarro J. Clinical manifestations, treatment and outcome of Paecilomyces lilacinus infections. Clin Microbiol Infect 2006; 12: 948-960.
8. Guarro J, Gams W, Pujol I, Gene J. Acremonium species: new emerging fungal opportunists-in vitro antifungal susceptibilities and review. Clin Infect Dis 1997; 25: 1222-1229.
9. Okhravi N, Lightman S. Clinical manifestations, treatment and outcome of Paecilomyces lilacinus infections. Clin Microbiol Infect 2007; 13: 554.
10. Ullmann AJ, Cornely OA, Donnelly JP et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases. Clin Microbiol Infect 2012; 18: 1-8.
11. Brozek JL, Akl EA, Compalati E et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines part 3 of 3. The GRADE approach to developing recommendations. Allergy 2011; 66: 588-595.
12. Brouwers MC, Kho ME, Browman GP et al. Development of the AGREE II, part 1: performance, usefulness and areas for improvement. CMAJ 2010; 182: 1045-1052.
13. Austen B, McCarthy H, Wilkins B, Smith A, Duncombe A. Fatal disseminated Fusarium infection in acute lymphoblastic leukaemia in complete remission. J Clin Pathol 2001; 54: 488-490.
14. Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997; 90: 999-1008.
15. Guarro J, Nucci M, Akiti T, Gene J, Barreiro MD, Goncalves RT. Fungemia due to Fusarium sacchari in an immunosuppressed patient. J Clin Microbiol 2000; 38: 419-421.
16. Guarro J, Nucci M, Akiti T, Gene J. Mixed infection caused by two species of Fusarium in a human immunodeficiency virus-positive patient. J Clin Microbiol 2000; 38: 3460-3462.
17. Krcmery V Jr, Jesenska Z, Spanik S et al. Fungaemia due to Fusarium spp. in cancer patients. J Hosp Infect 1997; 36: 223-228.
18. Tortorano AM, Prigitano A, Dho G et al. Species distribution and in vitro antifungal susceptibility patterns of 75 clinical isolates of Fusarium spp. from northern Italy. Antimicrob Agents Chemother 2008; 52: 2683-2685.
19. Mayayo E, Pujol I, Guarro J. Experimental pathogenicity of four opportunist Fusarium species in a murine model. J Med Microbiol 1999; 48: 363-366.
20. Raad I, Tarrand J, Hanna H et al. Epidemiology, molecular mycology, and environmental sources of Fusarium infection in patients with cancer. Infect Control Hosp Epidemiol 2002; 23: 532-537.
21. Nucci M, Marr KA, Queiroz-Telles F et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis 2004; 38: 1237-1242.
22. Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin Infect Dis 2002; 35: 909-920.
23. Campo M, Lewis RE, Kontoyiannis DP. Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998-2009. J Infect 2010; 60: 331-337.
24. Lortholary O, Obenga G, Biswas P et al. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother 2010; 54: 4446-4450.
25. Hennequin C, Benkerrou M, Gaillard JL, Blanche S, Fraitag S. Role of granulocyte colony-stimulating factor in the management of infection with Fusarium oxysporum in a neutropenic child. Clin Infect Dis 1994; 18: 490-491.
26. Marom ER. "CT of the solitary pulmonary nodule"-a commentary. AJR Am J Roentgenol 2008; 190: 1154-1155.
27. Marom ER, Holmes A, Bruzzi J, Truong M, O'Sullivan PJ, Kontoyiannis DP. Imaging of pulmonary fusariosis in patients with hematologic malignancies. Am J Roentgenol 2008; 190: 1605-1609.
28. O'Donnell K, Sutton DA, Rinaldi MG et al. Internet-accessible DNA sequence database for identifying fusaria from human and animal infections. J Clin Microbiol 2010; 48: 3708-3718.
29. Hennequin C, Abachin E, Symoens F et al. Identification of Fusarium species involved in human infections by 28S rRNA gene sequencing. J Clin Microbiol 1999; 37: 3586-3589.
30. Lau A, Sorrell TC, Lee O, Stanley K, Halliday C. Colony multiplex-tandem PCR for rapid, accurate identification of fungal cultures. J Clin Microbiol 2008; 46: 4058-4060.
31. Buelow DR, Gu Z, Walsh TJ, Hayden RT. Evaluation of multiplexed PCR and liquid-phase array for identification of respiratory fungal pathogens. Med Mycol 2012; 50: 775-780.
32. Liao MH, Lin JF, Li SY. Application of a multiplex suspension array for rapid and simultaneous identification of clinically important mold pathogens. Mol Cell Probes 2012; 26: 188-193.
33. Healy M, Reece K, Walton D et al. Use of the Diversi Lab System for species and strain differentiation of Fusarium species isolates. J Clin Microbiol 2005; 43: 5278-5280.
34. Marinach-Patrice C, Lethuillier A, Marly A et al. Use of mass spectrometry to identify clinical Fusarium isolates. Clin Microbiol Infect 2009; 15: 634-642.
35. De Carolis E, Posteraro B, Lass-Flörl C et al. Species identification of Aspergillus, Fusarium and Mucorales with direct surface analysis by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Clin Microbiol Infect 2012; 18: 475-484.
36. Landlinger C, Preuner S, Baskova L et al. Diagnosis of invasive fungal infections by a real-time panfungal PCR assay in immunocompromised pediatric patients. Leukemia 2010; 24: 2032-2038.
37. Landlinger C, Baskova L, Preuner S, Willinger B, Buchta V, Lion T. Identification of fungal species by fragment length analysis of the internally transcribed spacer 2 region. Eur J Clin Microbiol Infect Dis 2009; 28: 613-622.
38. Lau A, Chen S, Sorrell T et al. Development and clinical application of a panfungal PCR assay to detect and identify fungal DNA in tissue specimens. J Clin Microbiol 2007; 45: 380-385.
39. Spiess B, Seifarth W, Hummel M et al. DNA microarray-based detection and identification of fungal pathogens in clinical samples from neutropenic patients. J Clin Microbiol 2007; 45: 3743-3753.
40. Ahmad S, Khan ZU, Theyyathel AM. Development of a nested PCR assay for the detection of Fusarium solani DNA and its evaluation in the diagnosis of invasive fusariosis using an experimental mouse model. Mycoses 2010; 53: 40-47.
41. Hue FX, Huerre M, Rouffault MA, de Bievre C. Specific detection of Fusarium species in blood and tissues by a PCR technique. J Clin Microbiol 1999; 37: 2434-2438.
42. Bernal-Martinez L, Buitrago MJ, Castelli MV, Rodriguez-Tudela JL, Cuenca-Estrella M. Detection of invasive infection caused by Fusarium solani and non-Fusarium solani species using a duplex quantitative PCR-based assay in a murine model of fusariosis. Med Mycol 2012; 50: 270-275.
43. Lau A, Sorrell TC, Chen S, Stanley K, Iredell J, Halliday C. Multiplex tandem PCR: a novel platform for rapid detection and identification of fungal pathogens from blood culture specimens. J Clin Microbiol 2008; 46: 3021-3027.
44. Odabasi Z, Mattiuzzi G, Estey E et al. β-d-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39: 199-205.
45. Ostrosky-Zeichner L, Alexander BD, Kett DH et al. Multicenter clinical evaluation of the (1->3) β-d-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41: 654-659.
46. Tortorano AM, Esposto MC, Prigitano A et al. Cross-reactivity of Fusarium spp. in the Aspergillus galactomannan enzyme-linked immunosorbent assay. J Clin Microbiol 2011; 50: 1051-1053.
47. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Garcia-Effron G, Monzon A, Rodriguez-Tudela JL. In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi. Antimicrob Agents Chemother 2005; 49: 5136-5138.
48. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Buitrago MJ, Monzon A, Rodriguez-Tudela JL. Head-to-head comparison of the activities of currently available antifungal agents against 3, 378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 2006; 50: 917-921.
49. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12, 052 fungal isolates: review of the literature. Rev Iberoam Micol 2003; 20: 121-136.
50. Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, Rex JH. In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results. Antimicrob Agents Chemother 2002; 46: 3298-3300.
51. Arikan S, Lozano-Chiu M, Paetznick V, Nangia S, Rex JH. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species. J Clin Microbiol 1999; 37: 3946-3951.
52. Espinel-Ingroff A, Chaturvedi V, Fothergill A, Rinaldi MG. Optimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study. J Clin Microbiol 2002; 40: 3776-3781.
53. Meletiadis J, Meis JF, Mouton JW, Donnelly JP, Verweij PE. Comparison of NCCLS and 3-(4, 5-dimethyl-2-thiazyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method. J Clin Microbiol 2000; 38: 2949-2954.
54. Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 2004; 42: 4419-4431.
55. Szekely A, Johnson EM, Warnock DW. Comparison of E-test and broth microdilution methods for antifungal drug susceptibility testing of molds. J Clin Microbiol 1999; 37: 1480-1483.
56. Rombaux P, Eloy P, Bertrand B, Delos M, Doyen C. Lethal disseminated Fusarium infection with sinus involvement in the immunocompromised host: case report and review of the literature. Rhinology 1996; 34: 237-241.
57. Anaissie EJ, Rinaldi MG. Fusarium and the immunocompromised host: liaisons dangeureuses. N Y State J Med 1990; 90: 586-587.
58. Lupinetti FM, Giller RH, Trigg ME. Operative treatment of Fusarium fungal infection of the lung. Ann Thorac Surg 1990; 49: 991-992.
59. Lupinetti FM, Behrendt DM, Giller RH, Trigg ME, de Alarcon P. Pulmonary resection for fungal infection in children undergoing bone marrow transplantation. J Thorac Cardiovasc Surg 1992; 104: 684-687.
60. Perfect JR, Marr KA, Walsh TJ et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36: 1122-1131.
61. Raad II, Hachem RY, Herbrecht R et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006; 42: 1398-1403.
62. Baden LR, Katz JT, Fishman JA et al. Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy. Transplantation 2003; 76: 1632-1637.
63. Makowsky MJ, Warkentin DI, Savoie ML. Caspofungin and amphotericin B for disseminated Fusarium verticillioides in leukemia. Ann Pharmacother 2005; 39: 1365-1366.
64. Guzman-Cottrill JA, Zheng X, Chadwick EG. Fusarium solani endocarditis successfully treated with liposomal amphotericin B and voriconazole. Pediatr Infect Dis J 2004; 23: 1059-1061.
65. Durand-Joly I, Alfandari S, Benchikh Z et al. Successful outcome of disseminated Fusarium infection with skin localization treated with voriconazole and amphotericin B-lipid complex in a patient with acute leukemia. J Clin Microbiol 2003; 41: 4898-4900.
66. Ho DY, Lee JD, Rosso F, Montoya JG. Treating disseminated fusariosis: amphotericin B, voriconazole or both? Mycoses 2007; 50: 227-231.
67. Rothe A, Seibold M, Hoppe T et al. Combination therapy of disseminated Fusarium oxysporum infection with terbinafine and amphotericin B. Ann Hematol 2004; 83: 394-397.
68. Howden BP, Slavin MA, Schwarer AP, Mijch AM. Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur J Clin Microbiol Infect Dis 2003; 22: 111-113.
69. Velasco E, Martins CA, Nucci M. Successful treatment of catheter-related fusarial infection in immunocompromised children. Eur J Clin Microbiol Infect Dis 1995; 14: 697-699.
70. Rodriguez CA, Lujan-Zilbermann J, Woodard P, Andreansky M, Adderson EE. Successful treatment of disseminated fusariosis. Bone Marrow Transplant 2003; 31: 411-412.
71. Dignani MC, Anaissie EJ, Hester JP et al. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study. Leukemia 1997; 11: 1621-1630.
72. Spielberger RT, Falleroni M, Coene AJ, Larson RA. Concomitant amphotericin B therapy, granulocyte transfusions, and GM-CSF administration for disseminated infection with Fusarium in a granulocytopenic patient. Clin Infect Dis 1993; 16: 528-530.
73. Helm TN, Longworth DL, Hall GS, Bolwell BJ, Fernandez B, Tomecki KJ. Case report and review of resolved fusariosis. J Am Acad Dermatol 1990; 23: 393-398.
74. Merz WG, Karp JE, Hoagland M, Jett-Goheen M, Junkins JM, Hood AF. Diagnosis and successful treatment of fusariosis in the compromised host. J Infect Dis 1988; 158: 1046-1055.
75. Anaissie EJ, Stratton SL, Dignani MC et al. Cleaning patient shower facilities: a novel approach to reducing patient exposure to aerosolized Aspergillus species and other opportunistic molds. Clin Infect Dis 2002; 35: E86-E88.
76. Anaissie EJ, Kuchar RT, Rex JH et al. Fusariosis associated with pathogenic Fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections. Clin Infect Dis 2001; 33: 1871-1878.
77. Short DP, O'Donnell K, Zhang N, Juba JH, Geiser DM. Widespread occurrence of diverse human pathogenic types of the fungus Fusarium detected in plumbing drains. J Clin Microbiol 2011; 49: 4264-4272.
78. Bourgeois GP, Cafardi JA, Sellheyer K, Andea AA. Disseminated Fusarium infection originating from paronychia in a neutropenic patient: a case report and review of the literature. Cutis 2010; 85: 191-194.
79. Panackal AA, Marr KA. Scedosporium/Pseudallescheria infections. Semin Respir Crit Care Med 2004; 25: 171-181.
80. Marco de Lucas E, Sadaba P, Lastra Garcia-Baron P et al. Cerebral scedosporiosis: an emerging fungal infection in severe neutropenic patients: CT features and CT pathologic correlation. Eur Radiol 2006; 16: 496-502.
81. Pagano L, Caira M, Falcucci P, Fianchi L. Fungal CNS infections in patients with hematologic malignancy. Expert Rev Anti Infect Ther 2005; 3: 775-785.
82. Rüchel R, Wilichowski E. Cerebral Pseudallescheria mycosis after near-drowning. Mycoses 1995; 38: 473-475.
83. Gari M, Fruit J, Rousseaux P et al. Scedosporium (Monosporium) apiospermum: multiple brain abscesses. Sabouraudia 1985; 23: 371-376.
84. Bouza E, Munoz P. Invasive infections caused by Blastoschizomyces capitatus and Scedosporium spp. Clin Microbiol Infect 2004; 10: 76-85.
85. Cortez KJ, Roilides E, Quiroz-Telles F et al. Infections caused by Scedosporium spp. Clin Microbiol Rev 2008; 21: 157-197.
86. Elsayed S, Lannigan R, Chin-Yee I. Scedosporium prolificans fungemia. Can J Infect Dis 1999; 10: 75-76.
87. Montejo M, Muñiz ML, Zárraga S et al. Case Reports. Infection due to Scedosporium apiospermum in renal transplant recipients: a report of two cases and literature review of central nervous system and cutaneous infections by Pseudallescheria boydii/Sc. apiospermum. Mycoses 2002; 45: 418-427.
88. Lackner M, de Hoog GS. Scedosporium spp.: emerging agents of systemic disease. J Invasive Fungal Infect 2011; 5: 43-47.
89. Katragkou A, Dotis J, Kotsiou M, Tamiolaki M, Roilides E. Scedosporium apiospermum infection after near-drowning. Mycoses 2007; 50: 412-421.
90. Baumgartner BJ, Rakita RM, Backous DD. Scedosporium apiospermum otomycosis. Am J Otolaryngol 2007; 28: 254-256.
91. Bhat SV, Paterson DL, Rinaldi MG, Veldkamp PJ. Scedosporium prolificans brain abscess in a patient with chronic granulomatous disease: successful combination therapy with voriconazole and terbinafine. Scand J Infect Dis 2007; 39: 87-90.
92. Chen FK, Chen SD, Tay-Kearney ML. Intravitreal voriconazole for the treatment of endogenous endophthalmitis caused by Scedosporium apiospermum. Clin Experiment Ophthalmol 2007; 35: 382-385.
93. Dalton PA, Munckhof WJ, Walters DW. Scedosporium prolificans: an uncommon cause of septic arthritis. ANZ J Surg 2006; 76: 661-663.
94. Koga T, Kitjima T, Tanaka R et al. Chronic pulmonary scedosporiosis simulating aspergillosis. Respirology 2005; 10: 682-684.
95. Verghese S, Padmaja P, Chellamma MT, Leelavathy S, Nayar P. Prosthetic valve endocarditis caused by Scedosporium apiospermum. Indian J Med Microbiol 2005; 23: 264-266.
96. Husain S, Munoz P, Forrest G et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis 2005; 40: 89-99.
97. Madrigal V, Alonso J, Bureo E, Figols FJ, Salesa R. Fatal meningoencephalitis caused by Scedosporium inflatum (Scedosporium prolificans) in a child with lymphoblastic leukemia. Eur J Clin Microbiol Infect Dis 1995; 14: 601-603.
98. Nenoff P, Gütz U, Tintelnot K et al. Disseminated mycosis due to Scedosporium prolificans in an AIDS patient with Burkitt lymphoma. Mycoses 1996; 39: 461-465.
99. Rogasi PG, Zanazzi M, Nocentini J et al. Disseminated Scedosporium apiospermum infection in renal transplant recipient: long-term successful treatment with voriconazole: a case report. Transplant Proc 2007; 39: 2033-2035.
100. Musk M, Chambers D, Chin W, Muray R, Gabbay E. Successful treatment of disseminated Scedosporium infection in 2 lung transplant recipients: review of the literature and recommendations for management. J Heart Lung Transplant 2006; 25: 1268-1272.
101. Uenotsuchi T, Moroi Y, Urabe K et al. Cutaneous Scedosporium apiospermum infection in an immunocompromised patient and a review of the literature. Acta Derm Venerol 2005; 85: 156-159.
102. Castiglioni B, Sutton DA, Rinaldi MG, Fung J, Kusne S. Pseudallescheria boydii (Anamorph Scedosporium apiospermum). Infection in solid organ transplant recipients in a tertiary medical center and review of the literature. Medicine 2002; 81: 333-348.
103. Revankar SG, Patterson JE, Sutton DA, Pullen R, Rinaldi MG. Disseminated phaeohyphomycosis: review of an emerging mycosis. Clin Infect Dis 2002; 34: 467-476.
104. Maertens J, Lagrou K, Deweerdt H et al. Disseminated infection by Scedosporium prolificans: an emerging fatality among haematology patients. Case report and review. Ann Hematol 2000; 79: 340-344.
105. Berenguer J, Rodriguez-Tudela JL, Richard C et al. Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature. Scedosporium prolificans Spanish Study Group. Medicine (Baltimore) 1997; 76: 256-265.
106. Kantarcioglu AS, Guarro J, de Hoog GS. Central nervous system infections by members of the Pseudallescheria boydii species complex in healthy and immunocompromised hosts: epidemiology, clinical characteristics and outcome. Mycoses 2008; 51: 275-290.
107. Bryan CS, DiSalvo AF, Kaufman L, Kaplan W, Brill AH, Abbott DC. Petriellidium boydii infection of the sphenoid sinus. Am J Clin Pathol 1980; 74: 846-851.
108. Dworzack DL, Clark RB, Borkowski WJ Jr et al. Pseudallescheria boydii brain abscess: association with near-drowning and efficacy of high-dose, prolonged miconazole therapy in patients with multiple abscesses. Medicine (Baltimore) 1989; 68: 218-224.
109. Garzoni C, Emonet S, Legout L et al. Atypical infections in tsunami survivors. Emerg Infect Dis 2005; 11: 1591-1593.
110. Blyth CC, Middleton P, Harun A, Sorrell T, Meyer W, Chen SC. Clinical associations and prevalence of Scedosporium spp. in Australian cystic fibrosis patients: identification of novel risk factors? Med Mycol 2010; 48: S37-S44.
111. Kesson AM, Bellemore MC, O'Mara TJ, Ellis DH, Sorrell TC. Scedosporium prolificans osteomyelitis in an immunocompetent child treated with a novel agent, hexadecylphospocholine (miltefosine), in combination with terbinafine and voriconazole: a case report. Clin Infect Dis 2009; 48: 1257-1261.
112. Zouhair R, Rougeron A, Razafimandimby B, Kobi A, Bouchara JP, Giraud S. Distribution of the different species of the Pseudallescheria boydii/Scedosporium apiospermum complex in French patients with cystic fibrosis. Med Mycol 2013; 51: 603-613.
113. Berenguer J, Diaz-Mediaialla J, Urra D, Munoz P. Central nervous system infection caused by Pseudallescheria boydii: case report and review. Rev Infect Dis 1989; 11: 890-896.
114. Nomdedeu J, Brunet S, Martino R, Altes A, Ausina V, Domingo-Albos A. Successful treatment of pneumonia due to Scedosporium apiospermum with itraconazole: case report. Clin Infect Dis 1993; 16: 731-733.
115. Walsh M, White L, Atkinson K, Enno A. Fungal Pseudoallescheria boydii lung infiltrates unresponsive to amphotericin B in leukaemic patients. Aust N Z J Med 1992; 22: 265-268.
116. Winer-Muram HT, Vargas S, Slobod K. Cavitary lung lesions in an immunosuppressed child. Chest 1994; 106: 937-938.
117. Daben R, de Lucas M, Cuesta L et al. Imaging findings of pulmonary infection caused by Scedosporium prolificans in a deep immunocompromised patient. Emerging Radiology 2008; 15: 47-49.
118. Rabodonirina M, Paulus S, Thevenet F et al. Disseminated Scedosporium prolificans (S. inflatum) infection after single-lung transplantation. Clin Infect Dis 1994; 19: 138-142.
119. Wood GM, McCormack JG, Muir DB et al. Clinical features of human infection with Scedosporium inflatum. Clin Infect Dis 1992; 14: 1027-1033.
120. Guarner J, Brandt ME. Histopathologic diagnosis of fungal infections in the 21st century. Clin Microbiol Rev 2011; 24: 247-280.
121. Lackner M, Najafzadeh MJ, Sun J, Lu Q, Hoog GS. Rapid identification of Pseudallescheria and Scedosporium strains by using rolling circle amplification. Appl Environ Microbiol 2012; 78: 126-133.
122. Lackner M, Rezusta A, Villuendas MC, Palacian MP, Meis JF, Klaassen CH. Infection and colonisation due to Scedosporium in Northern Spain. An in vitro antifungal susceptibility and molecular epidemiology study of 60 isolates. Mycoses 2011; 54: 12-21.
123. Lu Q, Gerrits von den Ende AH, Bakkers JM et al. Identification of Pseudallescheria and Scedosporium species by three molecular methods. J Clin Microbiol 2011; 49: 960-967.
124. Steinmann J, Schmidt D, Buer J, Rath PM. Discrimination of Scedosporium prolificans against Pseudallescheria boydii and Scedosporium apiospermum by semiautomated repetitive sequence-based PCR. Med Mycol 2011; 49: 475-483.
125. Lackner M, de Hoog GS, Verweij PE et al. Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species. Antimicrob Agents Chemother 2012; 56: 2635-2642.
126. Meletiadis J, Meis JF, Mouton JW et al. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother 2002; 46: 62-68.
127. Schemuth H, Dittmer S, Lackner M et al. In vitro activity of colistin as single agent and in combination with antifungals against filamentous fungi occurring in patients with cystic fibrosis. Mycoses 2013; 56: 297-303.
128. Phillips P, Forbes JC, Speert DP. Disseminated infection with Pseudallescheria boydii in a patient with chronic granulomatous disease: response to γ-interferon plus antifungal chemotherapy. Pediatr Infect Dis J 1991; 10: 536-539.
129. Hopwood V, Evans EG, Matthews J, Denning DW. Scedosporium prolificans, a multi-resistant fungus, from a U.K. AIDS patient. J Infect 1995; 30: 153-155.
130. Bouza E, Munoz P, Vega L, Rodriguez-Creixems M, Berenguer J, Escudero A. Clinical resolution of Scedosporium prolificans fungemia associated with reversal of neutropenia following administration of granulocyte colony-stimulating factor. Clin Infect Dis 1996; 23: 192-193.
131. Tong SY, Peleg AY, Yoong J, Handke R, Szer J, Slavin M. Breakthrough Scedosporium prolificans infection while receiving voriconazole prophylaxis in an allogeneic stem cell transplant recipient. Transpl Infect Dis 2007; 9: 241-243.
132. Gosbell IB, Toumasatos V, Yong J, Kuo RS, Ellis DH, Perrie RC. Cure of orthopaedic infection with Scedosporium prolificans, using voriconazole plus terbinafine, without the need for radical surgery. Mycoses 2003; 46: 233-236.
133. Li JY, Yong TY, Grove DI, Coates PT. Successful control of Scedosporium prolificans septic arthritis and probable osteomyelitis without radical surgery in a long-term renal transplant recipient. Transpl Infect Dis 2008; 10: 63-65.
134. Schwartz S, Reisman A, Troke PF. The efficacy of voriconazole in the treatment of 192 fungal central nervous system infections: a retrospective analysis. Infection 2011; 39: 201-210.
135. Verweij PE, Cox NJ, Meis JF. Oral terbinafine for treatment of pulmonary Pseudallescheria boydii infection refractory to itraconazole therapy. Eur J Clin Microbiol Infect Dis 1997; 16: 26-28.
136. Borman AM, Palmer MD, Delhaes L et al. Lack of standardization in the procedures for mycological examination of sputum samples from CF patients: a possible cause for variations in the prevalence of filamentous fungi. Med Mycol 2010; 48: S88-S97.
137. Luangsa-Ard J, Houbraken J, van Doorn T et al. Purpureocillium, a new genus for the medically important Paecilomyces lilacinus. FEMS Microbiol Lett 2011; 321: 141-149.
138. Chamilos G, Kontoyiannis D. Voriconazole-resistant disseminated Paecilomyces variotii infection in a neutropenic patient with leukaemia on voriconazole prophylaxis. J Infect 2005; 51: e225-e228.
139. Lott ME, Sheehan DJ, Davis LS. Paecilomyces lilacinus infection with a sporotrichoid pattern in a renal transplant patient. J Drugs Dermatol 2007; 6: 436-439.
140. van Schooneveld T, Freifeld A, Lesiak B, Kalil A, Sutton DA, Iwen PC. Paecilomyces lilacinus infection in a liver transplant patient: case report and review of the literature. Transpl Infect Dis 2008; 10: 117-122.
141. Orth B, Frei R, Itin PH et al. Outbreak of invasive mycoses caused by Paecilomyces lilacinus from a contaminated skin lotion. Ann Intern Med 1996; 125: 799-806.
142. Salle V, Lecuyer E, Chouaki T et al. Paecilomyces variotii fungemia in a patient with multiple myeloma: case report and literature review. J Infect 2005; 51: e93-e95.
143. Wang SM, Shieh CC, Liu C. Successful treatment of Paecilomyces variotii splenic abscesses: a rare complication in a previously unrecognized chronic granulomatous disease child. Diagn Microbiol Infect Dis 2005; 53: 149-152.
144. Shing MM, Ip M, Li CK, Chik KW, Yuen PM. Paecilomyces varioti fungemia in a bone marrow transplant patient. Bone Marrow Transplant 1996; 17: 281-283.
145. Saghrouni F, Saidi W, Ben Said Z et al. Cutaneous hyalohyphomycosis caused by Purpureocillium lilacinum in an immunocompetent patient: case report and review. Med Mycol 2013; 51: 664-668.
146. Tarkkanen A, Raivio V, Anttila VJ et al. Fungal endophthalmitis caused by Paecilomyces variotii following cataract surgery: a presumed operating room air-conditioning system contamination. Acta Ophthalmol Scand 2004; 82: 232-235.
147. Beaudreuil S, Buchler M, Al Najjar A et al. Acute septic arthritis after kidney transplantation due to Acremonium. Nephrol Dial Transplant 2003; 18: 850-851.
148. Summerbell RC, Gueidan C, Schroers HJ, de Hoog GS, Starink M, Arocha Rosete Y. Acremonium phylogenetic overveiw and revision of Gliomastix, Scarocladium and Trichothecium. Persoonia 2011; 68: 139-162.
149. Das S, Saha R, Dar SA, Ramachandran VG. Acremonium species: a review of the etiological agents of emerging hyalohyphomycosis. Mycopathologia 2010; 170: 361-375.
150. Geyer AS, Fox LP, Husain S, Della-Latta P, Grossman ME. Acremonium mycetoma in a heart transplant recipient. J Am Acad Dermatol 2006; 55: 1095-1100.
151. Khan Z, Al-Obaid K, Ahmad S, Ghani AA, Joseph L, Chandy R. Acremonium kiliense: reappraisal of its clinical significance. J Clin Microbiol 2011; 49: 2342-2347.
152. Miyakis S, Velegraki A, Delikou S et al. Invasive Acremonium strictum infection in a bone marrow transplant recipient. Pediatr Infect Dis J 2006; 25: 273-275.
153. Warris A, Wesenberg F, Gaustad P, Verweij PE, Abrahamsen TG. Acremonium strictum fungaemia in a paediatric patient with acute leukaemia. Scand J Infect Dis 2000; 32: 442-444.
154. Weissgold DJ, Orlin SE, Sulewski ME, Frayer WC, Eagle RC Jr. Delayed-onset fungal keratitis after endophthalmitis. Ophtalmology 1998; 105: 258-262.
155. McGinnis MR, Pasarell L, Sutton DA, Fothergill AW, Cooper CR Jr, Rinaldi MG. In vitro activity of voriconazole against selected fungi. Med Mycol 1998; 36: 239-242.
156. Sabatelli F, Patel R, Mann PA et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006; 50: 2009-2015.
157. Perdomo H, Sutton DA, Garcia D et al. Spectrum of clinically relevant Acremonium species in the United States. J Clin Microbiol 2011; 49: 243-256.
158. Herbrecht R, Letscher-Bru V, Fohrer C et al. Acremonium strictum pulmonary infection in a leukemic patient successfully treated with posaconazole after failure of amphotericin B. Eur J Clin Microbiol Infect Dis 2002; 21: 814-817.
159. Mattei D, Mordini N, Lo Nigro C et al. Successful treatment of Acremonium fungemia with voriconazole. Mycoses 2003; 46: 511-514.
160. Szombathy SP, Chez MG, Laxer RM. Acute septic arthritis due to Acremonium. J Rheumatol 1988; 15: 714-715.
161. Lopes JO, Alves SH, Rosa AC, Silva CB, Sarturi JC, Souza CA. Acremonium kiliense peritonitis complicating continuous ambulatory peritoneal dialysis: report of two cases. Mycopathologia 1995; 131: 83-85.
162. Aguilar C, Pujol I, Guarro J. In vitro antifungal susceptibilities of Scopulariopsis isolates. Antimicrob Agents Chemother 1999; 43: 1520-1522.
163. Gupta AK, Gregurek-Novak T. Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes. Dermatology 2001; 202: 235-238.
164. Onsberg P. Scopulariopsis brevicaulis in nails. Dermatologica 1980; 161: 259-264.
165. Del Prete A, Sepe G, Ferrante M, Loffredo C, Masciello M, Sebastiani A. Fungal keratitis due to Scopulariopsis brevicaulis in an eye previously suffering from herpetic keratitis. Ophthalmologica 1994; 208: 333-335.
166. Hennequin C, el-Bez M, Trotoux J, Simonet M. Scopulariopsis brevicaulis otomycosis after tympanoplasty. Ann Otolaryngol Chir Cervicofac 1994; 111: 353-354.
167. Jabor MA, Greer DL, Amedee RG. Scopulariopsis: an invasive nasal infection. Am J Rhinol 1998; 12: 367-371.
168. Gentry LO, Nasser MM, Kielhofner M. Scopulariopsis endocarditis associated with Duran ring valvuloplasty. Tex Heart Inst J 1995; 22: 81-85.
169. Migrino RQ, Hall GS, Longworth DL. Deep tissue infections caused by Scopulariopsis brevicaulis: report of a case of prosthetic valve endocarditis and review. Clin Infect Dis 1995; 21: 672-674.
170. Miossec C, Morio F, Lepoivre T et al. Fatal invasive infection with fungemia due to Microascus cirrosus after heart and lung transplantation in a patient with cystic fibrosis. J Clin Microbiol 2011; 49: 2743-2747.
171. Iwen PC, Schutte SD, Florescu DF, Noel-Hurst RK, Sigler L. Invasive Scopulariopsis brevicaulis infection in an immunocompromised patient and review of prior cases caused by Scopulariopsis and Microascus species. Mycoses 2012; 50: 561-569.
172. Ng KP, Soo-Hoo TS, Na SL, Gan GG, Sangkar JV, Teh AK. Scopulariopsis brevicaulis infection in a patient with acute myeloid leukemia. Med J Malaysia 2003; 58: 608-612.
173. Mohammedi I, Piens MA, Audigier-Valette C et al. Fatal Microascus trigonosporus (anamorph Scopulariopsis) pneumonia in a bone marrow transplant recipient. Eur J Clin Microbiol Infect Dis 2004; 23: 215-217.
174. Nwabuisi C, Salami AK, Abdullahi NA, Agbede OO. Scopulariopsis associated meningitis in adult Nigerian AIDS patient-a case report. West Afr J Med 2003; 22: 364-365.
175. Martel J, Faisant M, Lebeau B, Pinel C, Feray C, Feuilhade M. Subcutaneous mycosis due to Scopulariopsis brevicaulis in an immunocompromised patient. Ann Dermatol Venerol 2001; 128: 130-133.
176. Sellier P, Monsuez JJ, Lacroix C et al. Recurrent subcutaneous infection due to Scopulariopsis brevicaulis in a liver transplant recipient. Clin Infect Dis 2000; 30: 820-823.
177. Phillips P, Wood WS, Phillips G, Rinaldi MG. Invasive hyalohyphomycosis caused by Scopulariopsis brevicaulis in a patient undergoing allogeneic bone marrow transplant. Diagn Microbiol Infect Dis 1989; 12: 429-432.
178. Neglia JP, Hurd DD, Ferrieri P, Snover DC. Invasive Scopulariopsis in the immunocompromised host. Am J Med 1987; 83: 1163-1166.
179. Wheat LJ, Bartlett M, Ciccarelli M, Smith JW. Opportunistic Scopulariopsis pneumonia in an immunocompromised host. South Med J 1984; 77: 1608-1609.
180. Hart AP, Sutton DA, McFeeley PJ, Kornfeld M. Cerebral phaeohyphomycosis caused by a dematiaceous Scopulariopsis species. Clin Neuropathol 2001; 20: 224-228.
181. Guinea J, Pelaez T, Recio S, Torres-Narbona M, Bouza E. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1, 007 isolates of zygomycete, Candida, Aspergillus, Fusarium and Scedosporium species. Antimicrob Agents Chemother 2008; 52: 1396-1400.
182. Linares MJ, Charriel G, Solis F, Rodriguez F, Ibarra A, Casal M. Susceptibility of filamentous fungi to voriconazole tested by two microdilution methods. J Clin Microbiol 2005; 43: 250-253.
183. Pfaller MA, Marco F, Messer SA, Jones RN. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743, 792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis 1998; 30: 251-255.
184. Meletiadis J, Mouton JW, Rodriguez-Tudela JL, Meis JF, Verweij PE. In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans. Antimicrob Agents Chemother 2000; 44: 470-472.
185. Espinel-Ingroff A, Johnson E, Hockey H, Troke P. Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies. J Antimicrob Chemother 2008; 61: 616-620.
186. Hope WW, Castagnola E, Groll A et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect 2012; 18: 38-52.
187. Trifilio S, Pennick G, Pi J et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007; 109: 1532-1535.
188. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46: 201-211.
189. Brüggemann RJ, Donnelly JP, Aarnoutse RE et al. Therapeutic drug monitoring of voriconazole. Ther Drug Monit 2008; 30: 403-411.
190. Dignani MC, Anaissie E. Human fusariosis. Clin Microbiol Infect 2004; 10: 67-75.
191. Hayden RT, Isotalo PA, Parrett T et al. In situ hybridization for the differentiation of Aspergillus, Fusarium and Pseudallescheria species in tissue section. Diagn Mol Pathol 2003; 12: 21-26.
192. Montone KT. Differentiation of Fusarium from Aspergillus species by colorimetric in situ hybridization in formalin-fixed, paraffin-embedded tissue sections using dual fluorogenic-labeled LNA probes. Am J Clin Pathol 2009; 132: 866-870.
193. Debourgogne A, de Hoog S, Lozniewski A, Machouart M. Amphotericin B and voriconazole susceptibility profiles for the Fusarium solani species complex: comparison between the E-test and CLSI M38-A2 microdilution methodology. Eur J Clin Microbiol Infect Dis 2012; 31: 615-618.
194. Guarro J. Lessons from animal studies for the treatment of invasive human infections due to uncommon fungi. J Antimicrob Chemother 2011; 66: 1447-1466.
195. Wiederhold NP, Najvar LK, Bocanegra R, Graybill JR, Patterson TF. Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani. Antimicrob Agents Chemother 2010; 54: 1055-1059.
196. Rojas R, Molina JR, Jarque I et al. Outcome of antifungal combination therapy for invasive mold infections in hematological patients is independent of the chosen combination. Mediterr J Hematol Infect Dis 2012; 4: e2012011.
197. Peman J, Salavert M, Canton E et al. Voriconazole in the management of nosocomial invasive fungal infections. Ther Clin Risk Manag 2006; 2: 129-158.
198. Jensen TG, Gahrn-Hansen B, Arendrup M, Bruun B. Fusarium fungaemia in immunocompromised patients. Clin Microbiol Infect 2004; 10: 499-501.
199. Musa MO, Al Eisa A, Halim M et al. The spectrum of Fusarium infection in immunocompromised patients with haematological malignancies and in non-immunocompromised patients: a single institution experience over 10 years. Br J Haematol 2000; 108: 544-548.
200. Patterson TS, Barton LL, Shehab ZM, Hutter JJ. Amphotericin B lipid complex treatment of a leukemic child with disseminated Fusarium solani infection. Clin Pediatr (Phila) 1996; 35: 257-260.
201. Edupuganti S, Rouphael N, Mehta A et al. Fusarium falciforme vertebral abscess and osteomyelitis: case report and molecular classification. J Clin Microbiol 2011; 49: 2350-2353.
202. Moschovi M, Trimis G, Anastasopoulos J, Kanariou M, Raftopoulou A, Tzortzatou-Stathopoulou F. Subacute vertebral osteomyelitis in a child with diabetes mellitus associated with Fusarium. Pediatr Int 2004; 46: 740-742.
203. Brint JM, Flynn PM, Pearson TA, Pui CH. Disseminated fusariosis involving bone in an adolescent with leukemia. Pediatr Infect Dis J 1992; 11: 965-968.
204. Sierra-Hoffman M, Paltiyevich-Gibson S, Carpenter JL, Hurley DL. Fusarium osteomyelitis: case report and review of the literature. Scand J Infect Dis 2005; 37: 237-240.
205. Bader M, Jafri AK, Krueger T, Kumar V. Fusarium osteomyelitis of the foot in a patient with diabetes mellitus. Scand J Infect Dis 2003; 35: 895-896.
206. Horre R, Marklein G, Siekmeier R, Reiffert SM. Detection of hyphomycetes in the upper respiratory tract of patients with cystic fibrosis. Mycoses 2011; 54: 514-522.
207. Cimon B, Carrere J, Vinatier JF, Chazalette JP, Chabasse D, Bouchara JP. Clinical significance of Scedosporium apiospermum in patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 2000; 19: 53-56.
208. Summerbell RC. The benomyl test as a fundamental diagnostic method for medical mycology. J Clin Microbiol 1993; 31: 572-577.
209. Horre R, Marklein G, Siekmeier R, Nidermajer S, Reiffert SM. Selective isolation of Pseudallescheria and Scedosporium species from respiratory tract specimens of cystic fibrosis patients. Respiration 2009; 77: 320-324.
210. Riddel J IV, Chenoweth CE, Kauffman CA. Disseminated Scedosporium apiospermum infection in a previously healthy woman with HELLP syndrome. Mycoses 2004; 47: 442-446.
211. Zhou X, Kong F, Sorrell TC, Wang H, Duan Y, Chen SC. Practical method for detection and identification of Candida, Aspergillus, and Scedosporium spp. by use of rolling-circle amplification. J Clin Microbiol 2008; 46: 2423-2427.
212. Walts AE. Pseudallescheria: an underdiagnosed fungus? Diagn Cytopathol 2001; 25: 153-157.
213. Kimura M, Ito H. Vesicular thick-walled swollen hyphae in pulmonary zygomycosis. Pathol Int 2009; 59: 175-178.
214. Castelli MV, Buitrago MJ, Bernal-Martinez L, Gomez-Lopez A, Rodriguez-Tudela JL, Cuenca-Estrella M. Development and validation of a quantitative PCR assay for diagnosis of scedosporiosis. J Clin Microbiol 2008; 46: 3412-3416.
215. Harun A, Blyth CC, Gilgado F, Middleton P, Chen SC, Meyer W. Development and validation of a multiplex PCR for detection of Scedosporium spp. in respiratory tract specimens from patients with cystic fibrosis. J Clin Microbiol 2011; 49: 1508-1512.
216. Lu Q, van den Ende AH, de Hoog GS et al. Reverse line blot hybridisation screening of Pseudallescheria/Scedosporium species in patients with cystic fibrosis. Mycoses 2011; 54: 5-11.
217. Del Chierico F, Masotti A, Onori M et al. MALDI-TOF MS proteomic phenotyping of filamentous and other fungi from clinical origin. J Proteomics 2012; 75: 3314-3330.
218. Coulibaly O, Marinach-Patrice C, Cassagne C, Piarroux R, Mazier D, Ranque S. Pseudallescheria/Scedosporium complex species identification by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Med Mycol 2011; 49: 621-626.
219. Lackner M, Klaassen CH, Meis JF, van den Ende AH, de Hoog GS. Molecular identification tools for sibling species of Scedosporium and Pseudallescheria. Med Mycol 2012; 50: 497-508.
220. Horré R, Schaal KP, Marklein G, de Hoog GS, Reiffert SM. Physiological typing of Pseudallescheria and Scedosporium strains using taxa profile, a semi-automated, 384-well microtitre system. Mycoses 2011; 54: 56-65.
221. Carrillo-Munoz AJ, Quindoz G, Ruesga M et al. In vitro antifungal susceptibility testing of filamentous fungi with Sensititre Yeast One. Mycoses 2006; 49: 293-297.
222. Carrillo-Munoz AJ, Quindoz G, del Valle O, Hernandez-Molina JM, Santos P. Antifungal activity of amphotericin B and itraconazole against filamentous fungi: comparison of the Sensititre Yeast One and NCCLS M38-a reference methods. J Chemother 2004; 16: 468-473.
223. Rodriguez MM, Pastor FJ, Salas V, Calvo E, Mayayo E, Guarro J. Experimental murine scedosporiosis: histopathology and azole treatment. Antimicrob Agents Chemother 2010; 54: 3980-3984.
224. Fortun J, Martin-Davila P, Sanchez MA et al. Voriconazole in the treatment of invasive mold infections in transplant recipients. Eur J Clin Microbiol Infect Dis 2003; 22: 408-413.
225. Heath CH, Slavin MA, Sorrell TC et al. Population-based surveillance for scedosporiosis in Australia: epidemiology, disease manifestations and emergence of Scedosporium aurantiacum infection. Clin Microbiol Infect 2009; 15: 689-693.
226. Takeuchi M, Yoshida C, Ota Y, Fujiwara Y. Deep skin infection of Scedosporium apiospermum in a patient with refractory idiopathic thrombocytopenic purpura. Intern Med 2011; 50: 1339-1343.
227. Luijk B, Ekkelenkamp MB, De Jong PA et al. Effective prolonged therapy with voriconazole in a lung transplant recipient with spondylodiscitis induced by Scedosporium apiospermum. Case Rep Infect Dis 2011; 2011: 460313.
228. Klopfenstein KJ, Rosselet R, Termuhlen A, Powell D. Successful treatment of Scedosporium pneumonia with voriconazole during AML therapy and bone marrow transplantation. Med Pediatr Oncol 2003; 41: 494-495.
229. Talbot TR, Hatcher J, Davis SF, Pierson RN III, Barton R, Dummer S. Scedosporium apiospermum pneumonia and sternal wound infection in a heart transplant recipient. Transplantation 2002; 74: 1645-1647.
230. Beier F, Kittan N, Holzmann T et al. Successful treatment of Scedosporium apiospermum soft tissue abscess with caspofungin and voriconazole in a severely immunocompromised patient with acute myeloid leukemia. Transpl Infect Dis 2010; 12: 538-542.
231. Barbaric D, Shaw PJ. Scedosporium infection in immunocompromised patients: successful use of liposomal amphotericin B and itraconazole. Med Pediatr Oncol 2001; 37: 122-125.
232. Meletiadis J, Mouton JW, Meis JF, Verweij PE. Combination chemotherapy for the treatment of invasive infections by Scedosporium prolificans. Clin Microbiol Infect 2000; 6: 336-337.
233. Horré R, Jovanic B, Marklein G et al. Fatal pulmonary scedosporiosis. Mycoses 2003; 46: 418-421.
234. Mellinghoff IK, Winston DJ, Mukwaya G, Schiller GJ. Treatment of Scedosporium apiospermum brain abscesses with posaconazole. Clin Infect Dis 2002; 34: 1648-1650.
235. Kowacs PA, Soares Silvado CE, Monteiro de Almeida S et al. Infection of the CNS by Scedosporium apiospermum after near drowning. Report of a fatal case and analysis of its confounding factors. J Clin Pathol 2004; 57: 205-207.
236. Buzina W, Feierl G, Haas D et al. Lethal brain abscess due to the fungus Scedosporium apiospermum (teleomorph Pseudallescheria boydii) after a near-drowning incident: case report and review of the literature. Med Mycol 2006; 44: 473-477.
237. Chakraborty A, Workman MR, Bullock PR. Scedosporium apiospermum brain abscess treated with surgery and voriconazole. Case report. J Neurosurg 2005; 103: 83-87.
238. Leechawengwongs M, Milindankura S, Liengudom A, Chanakul K, Viranuvatti K, Clongsusuek P. Multiple Scedosporium apiospermum brain abscesses after near-drowning successfully treated with surgery and long-term voriconazole: a case report. Mycoses 2007; 50: 512-516.
239. Tintelnot K, Wagner N, Seibold M, de Hoog GS, Horre R. Re-identification of clinical isolates of the Pseudallescheria boydii-complex involved in near-drowning. Mycoses 2008; 51: 11-16.
240. Symoens F, Knoop C, Schrooyen M et al. Disseminated Scedosporium apiospermum infection in a cystic fibrosis patient after double-lung transplantation. J Heart Lung Transplant 2006; 25: 603-607.
241. Borghi E, Iatta R, Manca A, Montagna MT, Morace G. Chronic airway colonization by Scedosporium apiospermum with a fatal outcome in a patient with cystic fibrosis. Med Mycol 2010; 48: S108-S113.
242. Vazquez-Tsuji O, Campos Rivera T, Rondan Zarate A, Mirabal Garcia M. Endobronchitis by Scedosporium apiospermum in a child with cystic fibrosis. Rev Iberoam Micol 2006; 23: 245-248.
243. Guignard S, Hubert D, DuPont B et al. Multifocal Scedosporium apiospermum spondylitis in a cystic fibrosis patient. J Cyst Fibros 2008; 7: 89-91.
244. Miraldi F, Anile M, Ruberto F et al. Scedosporium apiospermum atrial mycetomas after lung transplantation for cystic fibrosis. Transpl Infect Dis 2012; 14: 188-191.
245. Morio F, Horeau-Lnaglard D, Gay-Andrieu F et al. Disseminated Scedosporium/Pseudallescheria infection after double-lung transplantation in patients with cystic fibrosis. J Clin Microbiol 2010; 48: 1978-1982.
246. Sahi H, Avery RK, Minai OA et al. Scedosporium apiospermum (Pseudoallescheria boydii) infection in lung transplant recipients. J Heart Lung Transplant 2007; 26: 350-356.
247. Caggiano G, Cantisani P, Rolli M, Gianfreda CD, Pizzolante M, Montagna MT. The importance of a proper aetiological diagnosis in the management of patients with invasive mycoses: a case report of a brain abscess by Scedosporium apiospermum. Mycopathologia 2011; 172: 317-322.
248. Satirapoj B, Ruangkanchanasetr P, Treewatchareekorn S, Supasyndh O, Luesutthiviboon L, Supaporn T. Pseudallescheria boydii brain abscess in a renal transplant recipient: first case report in Southeast Asia. Transplant Proc 2008; 40: 2425-2427.
249. Mursch K, Trnovec S, Ratz H et al. Successful treatment of multiple Pseudallescheria boydii brain abscesses and ventriculitis/ependymitis in a 2-year-old child after a near-drowning episode. Childs Nerv Syst 2006; 22: 189-192.
250. Antachopoulos C, Katragkou A, Roilides E. Immunotherapy against invasive mold infections. Immunotherapy 2012; 4: 107-120.
251. Rodriguez-Tudela JL, Berenguer J, Guarro J et al. Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases. Med Mycol 2009; 47: 359-370.
252. Ortoneda M, Capilla J, Pastor FJ, Serena C, Guarro J. Interaction of granulocyte colony-stimulating factor and high doses of liposomal amphotericin B in the treatment of systemic murine scedosporiosis. Diagn Microbiol Infect Dis 2004; 50: 247-251.
253. Kanafani ZA, Comair Y, Kanj SS. Pseudallescheria boydii cranial osteomyelitis and subdural empyema successfully treated with voriconazole: a case report and literature review. Eur J Clin Microbiol Infect Dis 2004; 23: 836-840.
254. Cetrulo CL Jr, Leto Barone AA, Jordan K et al. A multi-disciplinary approach to the management of fungal osteomyelitis: current concepts in post-traumatic lower extremity reconstruction: a case report. Microsurgery 2012; 32: 144-147.
255. Mesfin FB, Tobin E, Adamo MA, Dirisio D. Fungal vertebral osteomyelitis due to Scedosporium apiospermum after near-drowning. J Neurosurg Spine 2008; 9: 58-61.
256. Levine NB, Kurokawa R, Fichtenbaum CJ, Howington JA, Kuntz C IV. An immunocompetent patient with primary Scedosporium apiospermum vertebral osteomyelitis. J Spinal Disord Tech 2002; 15: 425-430.
257. Hell M, Neureiter J, Wojna A et al. Post-traumatic Pseudallescheria apiosperma osteomyelitis: positive outcome of a young immunocompetent male patient due to surgical intervention and voriconazole therapy. Mycoses 2011; 54: 43-47.
258. Tammer I, Tintelnot K, Braun-Dullaeus RC et al. Infections due to Pseudallescheria/Scedosporium species in patients with advanced HIV disease-a diagnostic and therapeutic challenge. Int J Infect Dis 2011; 15: e422-e429.
259. Kantarcioglu AS, de Hoog GS, Guarro J. Clinical characteristics and epidemiology of pulmonary pseudallescheriasis. Rev Iberoam Micol 2012; 29: 1-13.
260. Nishio H, Utsumi T, Nakamura Y, Suzuki T, Kamei K, Saitoh T. Fungemia caused by Scedosporium prolificans in myelodysplastic syndrome. Kansenshogaku Zasshi 2012; 86: 22-26.
261. Troke P, Aguirrebengoa K, Arteaga C et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother 2008; 52: 1743-1750.
262. Cuenca-Estrella M, Alastruey-Izquierdo A, Alcazar-Fuoli L et al. In vitro activities of 35 double combinations of antifungal agents against Scedosporium apiospermum and Scedosporium prolificans. Antimicrob Agents Chemother 2008; 52: 1136-1139.
263. Idigoras P, Perez-Trallero E, Pineiro L et al. Disseminated infection and colonization by Scedosporium prolificans: a review of 18 cases, 1990-1999. Clin Infect Dis 2001; 32: E158-E165.
264. Meletiadis J, Mouton JW, Meis JF, Verweij PE. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother 2003; 47: 106-117.
265. Munoz P, Singh N, Bouza E. Treatment of solid organ transplant patients with invasive fungal infections: should a combination of antifungal drugs be used? Curr Opin Infect Dis 2006; 19: 365-370.
266. Ortoneda M, Capilla J, Pujol I et al. Liposomal amphotericin B and granulocyte colony-stimulating factor therapy in a murine model of invasive infection by Scedosporium prolificans. J Antimicrob Chemother 2002; 49: 525-529.
267. Spanevello M, Morris KL, Kennedy GA. Pseudoaneurysm formation by Scedosporium prolificans infection in acute leukaemia. Intern Med 2010; 40: 793.
268. Vagefi MR, Kim ET, Alvarado RG, Duncan JL, Howes EL, Crawford JB. Bilateral endogenous Scedosporium prolificans endophthalmitis after lung transplantation. Am J Ophthalmol 2005; 139: 370-373.
269. Whyte M, Irving H, O'Regan P, Nissen M, Siebert D, Labrom R. Disseminated Scedosporium prolificans infection and survival of a child with acute lymphoblastic leukemia. Pediatr Infect Dis J 2005; 24: 375-377.
270. Song MJ, Lee JH, Lee NY. Fatal Scedosporium prolificans infection in a paediatric patient with acute lymphoblastic leukaemia. Mycoses 2011; 54: 81-83.
271. Alvarez M, Lopez Ponga B, Rayon C et al. Nosocomial outbreak caused by Scedosporium prolificans (inflatum): four fatal cases in leukemic patients. J Clin Microbiol 1995; 33: 3290-3295.
272. Garcia-Ruiz JC, Amutio E, Hernandez I et al. Clinical resolution of Scedosporium prolificans pneumonia associated with treatment with liposomal amphotericin B in a patient with acute leukemia. Rev Iberoam Micol 1998; 15: 158-159.
273. Guarro J, Gaztelurrutia L, Marin J, Barcena J. Scedosporium inflatum, a new pathogenic fungus. Report of 2 cases with a fatal outcome. Enferm Infecc Microbiol Clin 1991; 9: 557-560.
274. Marin J, Sanz MA, Sanz GF et al. Disseminated Scedosporium inflatum infection in a patient with acute myeloblastic leukemia. Eur J Clin Microbiol Infect Dis 1991; 10: 759-761.
275. Pickles RW, Pacey DE, Muir DB, Merrell WH. Experience with infection by Scedosporium prolificans including apparent cure with fluconazole therapy. J Infect 1996; 33: 193-197.
276. Salesa R, Burgos A, Ondiviela R, Richard C, Quindos G, Ponton J. Fatal disseminated infection by Scedosporium inflatum after bone marrow transplantation. Scand J Infect Dis 1993; 25: 389-393.
277. del Palacio A, Garau M, Amor E et al. Case reports. Transient colonization with Scedosporium prolificans. Report of four cases in Madrid. Mycoses 2001; 44: 321-325.
278. Feltkamp MC, Kersten MJ, van der Lelie J, Burggraaf JD, de Hoog GS, Kuijper EJ. Fatal Scedosporium prolificans infection in a leukemic patient. Eur J Clin Microbiol Infect Dis 1997; 16: 460-464.
279. McKelvie PA, Wong EY, Chow LP, Hall AJ. Scedosporium endophthalmitis: two fatal disseminated cases of Scedosporium infection presenting with endophthalmitis. Clin Experiment Ophthalmol 2001; 29: 330-334.
280. Spielberger RT, Tegtmeier BR, O'Donnell MR, Ito JI. Fatal Scedosporium prolificans (S. inflatum) fungemia following allogeneic bone marrow transplantation: report of a case in the United States. Clin Infect Dis 1995; 21: 1067.
281. Wise KA, Speed BR, Ellis DH, Andrew JH. Two fatal infections in immunocompromised patients caused by Scedosporium inflatum. Pathology 1993; 25: 187-189.
282. Revankar SG, Sutton DA. Melanized fungi in human disease. Clin Microbiol Rev 2010; 23: 884-928.
283. Kumar B, Crawford GJ, Morlet GC. Scedosporium prolificans corneoscleritis: a successful outcome. Aust N Z J Ophthalmol 1997; 25: 169-171.
284. Horré R, Feil E, Stangel AP et al. Scedosporiosis of the brain with fatal outcome after traumatization of the foot. Case report. Mycoses 2000; 43: 33-36.
285. Garcia-Vidal C, Cabellos C, Ayats J, Font F, Ferran E, Fernandez-Viladrich P. Fungal postoperative spondylodiscitis due to Scedosporium prolificans. Spine J 2009; 9: e1-e7.
286. Steinbach WJ, Schell WA, Miller JL, Perfect JR. Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide. J Clin Microbiol 2003; 41: 3981-3985.
287. Lackner M, De Man FH, Eygendaal D et al. Severe prosthetic joint infection in an immunocompetent male patient due to a therapy refractory Pseudallescheria apiosperma. Mycoses 2011; 54: 22-27.
288. Benedict LM, Kusne S, Torre-Cisneros J, Hunt SJ. Primary cutaneous fungal infection after solid-organ transplantation: report of five cases and review. Clin Infect Dis 1992; 15: 17-21.
289. Blackwell V, Ahmed K, O'Docherty C, Hay RJ. Cutaneous hyalohyphomycosis caused by Paecilomyces lilacinus in a renal transplant patient. Br J Dermatol 2000; 143: 873-875.
290. Hall VC, Goyal S, Davis MD, Walsh JS. Cutaneous hyalohyphomycosis caused by Paecilomyces lilacinus: report of three cases and review of the literature. Int J Dermatol 2004; 43: 648-653.
291. Heinz T, Perfect J, Schell W, Ritter E, Ruff G, Serafin D. Soft-tissue fungal infections: surgical management of 12 immunocompromised patients. Plast Reconstr Surg 1996; 97: 1391-1399.
292. Wessolossky M, Haran JP, Bagchi K. Paecilomyces lilacinus olecranon bursitis in an immunocompromised host: case report and review. Diagn Microbiol Infect Dis 2008; 61: 354-357.
293. Wolfson JS, Sober AJ, Rubin RH. Dermatologic manifestations of infections in immunocompromised patients. Medicine (Baltimore) 1985; 64: 115-133.
294. Lee J, Yew WW, Chiu CS, Wong PC, Wong CF, Wang EP. Delayed sternotomy wound infection due to Paecilomyces variotii in a lung transplant recipient. J Heart Lung Transplant 2002; 21: 1131-1134.
295. Das A, MacLaughlin EF, Ross LA et al. Paecilomyces variotii in a pediatric patient with lung transplantation. Pediatr Transplant 2000; 4: 328-332.
296. Dharmasena FM, Davies GS, Catovsky D. Paecilomyces varioti pneumonia complicating hairy cell leukaemia. Br Med J (Clin Res Ed) 1985; 290: 967-968.
297. Gucalp R, Carlisle P, Gialanella P, Mitsudo S, McKitrick J, Dutscher J. Paecilomyces sinusitis in an immunocompromised adult patient: case report and review. Clin Infect Dis 1996; 23: 391-393.
298. Roque J, Navarro M, Toro G, Gonzalez I, Pimstein M, Venegas E. Paecilomyces lilacinus systemic infection in an immunocompromised child. Rev Med Chil 2003; 131: 77-80.
299. Chan-Tack KM, Thio CL, Miller NS, Karp CL, Ho C, Merz WG. Paecilomyces lilacinus fungemia in an adult bone marrow transplant recipient. Med Mycol 1999; 37: 57-60.
300. Keshtkar-Jahromi M, McTighe AH, Segalman KA, Fothergill AW, Campbell WN. Unusual case of cutaneous and synovial Paecilomyces lilacinus infection of hand successfully treated with voriconazole and review of published literature. Mycopathologia 2012; 174: 225-258.
301. Ezzedine K, Belin E, Guillet S et al. Cutaneous hyphomycosis due to Paecilomyces lilacinus. Acta Derm Venerol 2012; 92: 156-157.
302. Xiujiao X, Hong S, Ai-e X. Eumycetoma due to Acremonium falciforme acquired in China. Mycoses 2012; 55: e4-e7.
303. Lee MW, Kim JC, Choi JS, Kim KH, Greer DL. Mycetoma caused by Acremonium falciforme: successful treatment with itraconazole. J Am Acad Dermatol 1995; 32: 897-900.
304. Bangsgaard N, Saunte DM, Fokenberg M, Zachariae C. Serious adverse events reporting on systemic terbinafine: a Danish register-based study. Acta Derm Venerol 2011; 91: 358-359.